Electrome + ActiPatch: The Next Step
Therapeutic Layer That Every Wearable Platform Is Missing
Every major wearable brand—Oura, WHOOP, Apple Health, Samsung’s Galaxy Ring, Fitbit’s AI reboot—has mastered measurement. They track HRV, sleep, strain, temperature, stress, and recovery. They’ve built billion‑dollar businesses on sensing and interpreting physiology.
But none of them have a physical therapeutic modality.
They measure and advise.
They don’t intervene.
Electrome + BioElectronics Corp (BIEL) is the first platform that gives them exactly that: a safe, FDA‑cleared, ultra‑lightweight therapeutic engine that can close the loop between sensing and action.
The Closed‑Loop Future: Measure - Intervene - Measure
(Across Oura, WHOOP, Apple, Samsung, Fitbit)
All major wearables already detect:
HRV suppression from pain or inflammation
Sleep disruption
Stress signatures
Recovery deficits
Temperature deviations
Activity‑linked strain
Electrome + BIEL’s ActiPatch platform provides the missing half:
A non‑invasive, drug‑free therapeutic
FDA‑cleared PEMF hardware
Safe for continuous use
Already mass‑manufactured
Programmable and AI‑driven through Electrome’s layer
This enables the first consumer‑grade closed‑loop bioelectric health system:
Wearable detects inflammation, stress, or poor recovery
Electrome‑powered ActiPatch delivers targeted PEMF therapy
Wearable measures the physiological response
AI adjusts therapy timing and intensity
This is the “holy grail” of consumer health tech—turning passive measurement into active improvement.
Why Every Major Wearable Platform Needs This
Oura
Oura has built an $11B valuation on measurement alone. But to stay ahead of WHOOP, Apple, Samsung, and Fitbit’s AI relaunch, they need differentiated interventions, not just better metrics. Electrome + BIEL gives them a proprietary therapeutic layer and a defensible moat.
WHOOP
WHOOP’s entire model is strain → recovery → coaching.
Adding a therapeutic layer turns WHOOP from “telling you you’re overreached” into “helping you recover faster.”
Apple Health
Apple is pushing deeper into medical‑grade monitoring (AFib, fertility, mental health). A safe, FDA‑cleared, low‑power therapeutic patch fits perfectly into Apple’s “health services” roadmap.
Samsung Galaxy Ring (launching 2026)
Samsung is entering the ring market late. A therapeutic partnership would instantly differentiate Galaxy Ring from Oura and WHOOP.
Fitbit’s AI Relaunch
Fitbit is rebuilding its identity around AI‑driven health insights. Electrome + ActiPatch gives them a hardware‑based intervention to pair with those insights.
Why BIEL’s Hardware Is the Only Practical Option
BIEL’s ActiPatch/RecoveryRx platform is:
Lightweight
Battery‑efficient
Safe for continuous use
Already FDA‑cleared
Already mass‑manufactured
Low‑cost
Proven in pain and inflammation reduction
Now programmable through Electrome’s AI layer
This makes it the only therapeutic modality that can be:
Bundled with a wearable subscription
Sold as an accessory
Integrated into recovery programs
Used for sleep, stress, menstrual pain, inflammation, and injury recovery
Deployed at scale without regulatory delays
Why This Matters for BIEL
Electrome transforms BIEL from a niche PEMF patch maker into:
A therapeutic engine for global wearable platforms
A hardware OEM for consumer health giants
A predicate device provider enabling rapid regulatory expansion
A gateway into millions of users already tracking pain, sleep, and recovery
This is the kind of partnership that can 1000+× visibility and valuation.
The Strategic Pressure on Wearables
Oura, WHOOP, Apple, Samsung, and Fitbit are all racing to differentiate.
Measurement alone is no longer enough.
They need interventions.
Electrome + BIEL gives them:
A proprietary therapeutic
A new revenue stream
A defensible moat
A clinical‑grade expansion path
A shift from “tracking health” to improving health
Therapeutic Layer That Every Wearable Platform Is Missing
Every major wearable brand—Oura, WHOOP, Apple Health, Samsung’s Galaxy Ring, Fitbit’s AI reboot—has mastered measurement. They track HRV, sleep, strain, temperature, stress, and recovery. They’ve built billion‑dollar businesses on sensing and interpreting physiology.
But none of them have a physical therapeutic modality.
They measure and advise.
They don’t intervene.
Electrome + BioElectronics Corp (BIEL) is the first platform that gives them exactly that: a safe, FDA‑cleared, ultra‑lightweight therapeutic engine that can close the loop between sensing and action.
The Closed‑Loop Future: Measure - Intervene - Measure
(Across Oura, WHOOP, Apple, Samsung, Fitbit)
All major wearables already detect:
HRV suppression from pain or inflammation
Sleep disruption
Stress signatures
Recovery deficits
Temperature deviations
Activity‑linked strain
Electrome + BIEL’s ActiPatch platform provides the missing half:
A non‑invasive, drug‑free therapeutic
FDA‑cleared PEMF hardware
Safe for continuous use
Already mass‑manufactured
Programmable and AI‑driven through Electrome’s layer
This enables the first consumer‑grade closed‑loop bioelectric health system:
Wearable detects inflammation, stress, or poor recovery
Electrome‑powered ActiPatch delivers targeted PEMF therapy
Wearable measures the physiological response
AI adjusts therapy timing and intensity
This is the “holy grail” of consumer health tech—turning passive measurement into active improvement.
Why Every Major Wearable Platform Needs This
Oura
Oura has built an $11B valuation on measurement alone. But to stay ahead of WHOOP, Apple, Samsung, and Fitbit’s AI relaunch, they need differentiated interventions, not just better metrics. Electrome + BIEL gives them a proprietary therapeutic layer and a defensible moat.
WHOOP
WHOOP’s entire model is strain → recovery → coaching.
Adding a therapeutic layer turns WHOOP from “telling you you’re overreached” into “helping you recover faster.”
Apple Health
Apple is pushing deeper into medical‑grade monitoring (AFib, fertility, mental health). A safe, FDA‑cleared, low‑power therapeutic patch fits perfectly into Apple’s “health services” roadmap.
Samsung Galaxy Ring (launching 2026)
Samsung is entering the ring market late. A therapeutic partnership would instantly differentiate Galaxy Ring from Oura and WHOOP.
Fitbit’s AI Relaunch
Fitbit is rebuilding its identity around AI‑driven health insights. Electrome + ActiPatch gives them a hardware‑based intervention to pair with those insights.
Why BIEL’s Hardware Is the Only Practical Option
BIEL’s ActiPatch/RecoveryRx platform is:
Lightweight
Battery‑efficient
Safe for continuous use
Already FDA‑cleared
Already mass‑manufactured
Low‑cost
Proven in pain and inflammation reduction
Now programmable through Electrome’s AI layer
This makes it the only therapeutic modality that can be:
Bundled with a wearable subscription
Sold as an accessory
Integrated into recovery programs
Used for sleep, stress, menstrual pain, inflammation, and injury recovery
Deployed at scale without regulatory delays
Why This Matters for BIEL
Electrome transforms BIEL from a niche PEMF patch maker into:
A therapeutic engine for global wearable platforms
A hardware OEM for consumer health giants
A predicate device provider enabling rapid regulatory expansion
A gateway into millions of users already tracking pain, sleep, and recovery
This is the kind of partnership that can 1000+× visibility and valuation.
The Strategic Pressure on Wearables
Oura, WHOOP, Apple, Samsung, and Fitbit are all racing to differentiate.
Measurement alone is no longer enough.
They need interventions.
Electrome + BIEL gives them:
A proprietary therapeutic
A new revenue stream
A defensible moat
A clinical‑grade expansion path
A shift from “tracking health” to improving health
2
